2 terminated, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Birabresib: new trials by email Literature Review of Birabresib trials Research Report on Birabresib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) Birabresib - NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 13 | 2016-05-04 | 2021-01-27 |
| A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) Birabresib - Glioblastoma Multiforme | Phase 2 | Terminated | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 12 | 2014-10-29 | 2021-01-26 |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Birabresib - NUT Midline Carcinoma, Triple Negative Breast Cancer | Phase 1 | Completed | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 47 | 2014-10-23 | 2021-01-26 |
Triple Negative Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Merck Sharp & Dohme LLC (1)
2014 (2), 2015 (1)